Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Comparative Analysis of Serum Proteomes of Moyamoya Disease and Normal Controls

  • Koh, Eun-Jeong (Department of Neurosurgery, Chonbuk National University Medical School) ;
  • Kim, Han-Na (Department of Pharmacology, Chonbuk National University Medical School) ;
  • Ma, Tian-Ze (Department of Pharmacology, Chonbuk National University Medical School) ;
  • Choi, Ha-Young (Department of Neurosurgery, Chonbuk National University Medical School) ;
  • Kwak, Yong-Geun (Department of Pharmacology, Chonbuk National University Medical School)
  • Received : 2010.04.05
  • Accepted : 2010.06.14
  • Published : 2010.07.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : The etiology and pathogenesis of moyamoya disease remain unclear. Furthermore, the definitive diagnostic protein-biomarkers for moyamoya disease are still unknown. The present study analyzed serum proteomes from normal controls and moyamoya patients to identify novel serological biomarkers for diagnosing moyamoya disease. Methods : We compared the two-dimensional electrophoresis patterns of sera from moyamoya disease patients and normal controls and identified the differentially-expressed spots by matrix-assisted laser desorption/ionization-time-of flight mass spectrometry and electrospray ionization quadruple time-of-flight mass spectrometry. Results : We found and analyzed 22 differently-expressed proteomes. Two proteins were up-regulated. Twenty proteins were down-regulated. Complement C1 inhibitor protein and apolipoprotein C-III showed predominantly changed expressions (complement C1 inhibitor protein averaged a 7.23-fold expression in moyamoya patients as compared to controls, while apolipoprotein C-III averaged a 0.066-fold expression). Conclusion : Although our study had a small sample size, our proteomic data provide serologic clue proteins for understanding moyamoya disease.

Keywords

References

  1. Akita N, Nakase H, Kaido T, Kanemoto Y, Sakaki T : Protective effect of C1 esterase inhibitor on reperfusion injury in the rat middle cerebral artery occlusion model. Neurosurgery 52 : 395-400; discussion 400-401, 2003 https://doi.org/10.1227/01.NEU.0000043710.61233.B4
  2. Caillot F, Hiron M, Goria O, Gueudin M, Francois A, Scotte M, et al. : Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients. Am J Pathol 175 : 46-53, 2009 https://doi.org/10.2353/ajpath.2009.080850
  3. Chiang HL, Lyu RK, Tseng MY, Chang KH, Chang HS, Hsu WC, et al. : Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barre syndrome and other neurological disorders. Clin Chim Acta 405 : 143-147, 2009 https://doi.org/10.1016/j.cca.2009.04.022
  4. Fukui M, Kono S, Sueishi K, Ikezaki K : Moyamoya disease. Neuropathology 20 Suppl : S61-S64, 2000 https://doi.org/10.1046/j.1440-1789.2000.00300.x
  5. Fukuyama Y, Osawa M, Kanai N : Moyamoya disease (syndrome) and the Down syndrome. Brain Dev 14 : 254-256, 1992 https://doi.org/10.1016/S0387-7604(12)80242-7
  6. Heimann A, Takeshima T, Horstick G, Kempski O : C1-esterase inhibitor reduces infarct volume after cortical vein occlusion. Brain Res 838 : 210-213, 1999 https://doi.org/10.1016/S0006-8993(99)01740-0
  7. Hong SH, Wang KC, Kim SK, Cho BK, Park MH : Association of HLA-DR and -DQ genes with familial moyamoya disease in Koreans. J Korean Neurosurg Soc 46 : 558-563, 2009 https://doi.org/10.3340/jkns.2009.46.6.558
  8. Hosoda Y, Ikeda E, Hirose S : Histopathological studies on spontaneous occlusion of the circle of Willis (cerebrovascular moyamoya disease). Clin Neurol Neurosurg 99 Suppl 2 : S203-S208, 1997
  9. Hybelova M, Svatonova J, Sobek O, Adam P, Dolezil D, Adam D : Cerebrospinal fluid and serum prealbumin (transthyretin) in patients with multiple sclerosis (MS) : comparison of particular subgroups of MS patients. Folia Microbiol (Praha) 54 : 173-176, 2009 https://doi.org/10.1007/s12223-009-0027-4
  10. Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T : Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet 64 : 533-537, 1999 https://doi.org/10.1086/302243
  11. Ikeda H, Yoshimoto T : Specific genetic characteristics in patients with familial moyamoya disease. J Stroke Cerebrovasc Dis 14 : 244-250, 2005 https://doi.org/10.1016/j.jstrokecerebrovasdis.2005.06.005
  12. Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M : Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol 15 : 179-182, 2000 https://doi.org/10.1177/088307380001500307
  13. Kang HS, Kim SK, Cho BK, Kim YY, Hwang YS, Wang KC : Single nucleotide polymorphisms of tissue inhibitor of metalloproteinase genes in familial moyamoya disease. Neurosurgery 58 : 1074-1080; discussion 1074-1080, 2006 https://doi.org/10.1227/01.NEU.0000215854.66011.4F
  14. Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM : Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 114 : 681-687, 2006 https://doi.org/10.1161/CIRCULATIONAHA.106.622514
  15. Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, Lee KA, et al. : The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res 11 : R22, 2009 https://doi.org/10.1186/bcr2247
  16. Kwon JH, Park ST, Kim GD, You CR, Kim JD, Woo HY, et al. : [The value of serum retinol-binding protein 4 levels for determining disease severity in patients with chronic liver disease.] Korean J Hepatol 15 : 59-69, 2009 https://doi.org/10.3350/kjhep.2009.15.1.59
  17. Masuda J, Ogata J, Yutani C : Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke 24 : 1960-1967, 1993 https://doi.org/10.1161/01.STR.24.12.1960
  18. Nobili V, Alkhouri N, Alisi A, Ottino S, Lopez R, Manco M, et al. : Retinol-binding protein 4 : a promising circulating marker of liver damage in pediatric nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 7 : 575-579, 2009 https://doi.org/10.1016/j.cgh.2008.12.031
  19. Park JS, Oh KJ, Norwitz ER, Han JS, Choi HJ, Seong HS, et al. : Identification of proteomic biomarkers of preeclampsia in amniotic fluid using SELDI-TOF mass spectrometry. Reprod Sci 15 : 457-468, 2008 https://doi.org/10.1177/1933719108316909
  20. Sakurai K, Horiuchi Y, Ikeda H, Ikezaki K, Yoshimoto T, Fukui M, et al. : A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet 49 : 278-281, 2004 https://doi.org/10.1007/s10038-004-0143-6
  21. Scheler C, Lamer S, Pan Z, Li XP, Salnikow J, Jungblut P : Peptide mass fingerprint sequence coverage from differently stained proteins on two-dimensional electrophoresis patterns by matrix assisted laser desorption/ionization-mass spectrometry (MALDI-MS). Electrophoresis 19 : 918-927, 1998 https://doi.org/10.1002/elps.1150190607
  22. Soriano SG, Cowan DB, Proctor MR, Scott RM : Levels of soluble adhesion molecules are elevated in the cerebrospinal fluid of children with moyamoya syndrome. Neurosurgery 50 : 544-549, 2002
  23. Storini C, Rossi E, Marrella V, Distaso M, Veerhuis R, Vergani C, et al. : C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol Dis 19 : 10-17, 2005 https://doi.org/10.1016/j.nbd.2004.11.001
  24. Suzuki J, Takaku A : Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20 : 288-299, 1969 https://doi.org/10.1001/archneur.1969.00480090076012
  25. Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R, et al. : Epidemiological features of moyamoya disease in Japan : findings from a nationwide survey. Clin Neurol Neurosurg 99 Suppl 2 : S1-S5, 1997
  26. Yamauchi T, Houkin K, Tada M, Abe H : Familial occurrence of moyamoya disease. Clin Neurol Neurosurg 99 Suppl 2 : S162-S167, 1997
  27. Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, et al. : Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 31 : 930-935, 2000 https://doi.org/10.1161/01.STR.31.4.930
  28. Yoshimoto T, Houkin K, Takahashi A, Abe H : Evaluation of cytokines in cerebrospinal fluid from patients with moyamoya disease. Clin Neurol Neurosurg 99 Suppl 2 : S218-S220, 1997

Cited by

  1. Recent Advances in Moyamoya Disease: Pathophysiology and Treatment vol.14, pp.1, 2010, https://doi.org/10.1007/s11910-013-0423-7
  2. RATIONALIZATION OF SURGICAL TREATMENT FOR HEMORRHAGIC MOYAMOYA DISEASE: FROM LABORATORY BENCH RESEARCH, BIOMECHANICS TO META-ANALYSIS vol.19, pp.5, 2010, https://doi.org/10.1142/s0219519419500350
  3. iTRAQ-based Quantitative Proteomic Analysis of Dural Tissues Reveals Upregulated Haptoglobin to be a Potential Biomarker of Moyamoya Disease vol.17, pp.None, 2010, https://doi.org/10.2174/1570164617666191210103652
  4. Genetic and Proteomic Contributions to the Pathophysiology of Moyamoya Angiopathy and Related Vascular Diseases vol.14, pp.None, 2021, https://doi.org/10.2147/tacg.s252736